Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster

by Zacks Equity Research

Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.

Kinjel Shah headshot

5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

by Kinjel Shah

There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for December 7th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

Vivus (VVUS) Down 17% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y

by Zacks Equity Research

VIVUS (VVUS) reports narrower-than-expected loss in the third quarter. Sales increase year over year.

Why Is Vivus (VVUS) Down 6.4% Since Last Earnings Report?

by Zacks Equity Research

Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market

    by Zacks Equity Research

    VIVUS' (VVUS) Qsymia sales lackluster due to slow uptake of the drug and a competitive market.

      VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

      by Zacks Equity Research

      VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.

        VIVUS' PAH Candidate Data Positive in Early Stage Study

        by Zacks Equity Research

        VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.

          VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session

          by Zacks Equity Research

          VIVUS (VVUS) was a big mover last session, as the company saw its shares rise more than 10% on the day, amid huge volumes.

            Can The Uptrend Continue for VIVUS (VVUS)?

            by Zacks Equity Research

            Investors certainly have to be happy with VIVUS, Inc. (VVUS) and its short term performance

              3 Biotech Stocks Up in the Past Month on Industry Turnaround

              by Zacks Equity Research

              We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.

                VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher

                by Zacks Equity Research

                VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

                  VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

                  by Zacks Equity Research

                  VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

                    Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?

                    by Zacks Equity Research

                    VIVUS (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Orexigen Struggles as Contrave Commercialization Costs Rise

                      by Zacks Equity Research

                      Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

                        VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

                        by Zacks Equity Research

                        VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

                          Orexigen's (OREX) Contrave Sales Improving on Promotions

                          by Zacks Equity Research

                          Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

                            VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug

                            by Zacks Equity Research

                            VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.

                              VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?

                              by Zacks Equity Research

                              VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y

                                by Zacks Equity Research

                                VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.

                                  VIVUS Settles with Teva on Weight Management Drug Generic

                                  by Zacks Equity Research

                                  VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.

                                    BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

                                    by Zacks Equity Research

                                    BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

                                      Why is Corcept's Stock Up More Than 60% So Far This Year?

                                      by Zacks Equity Research

                                      Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.

                                        Roche (RHHBY) Launches Cobas Test for Bacterial Infections

                                        by Zacks Equity Research

                                        Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.